Navigation Links
Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
Date:5/15/2009

eceive further anthracycline treatment if their disease returns. Pixantrone has been designed to reduce the potential for these severe cardiotoxicities without sacrificing anti-cancer activity. It also can be administered through a peripheral vein rather than a central implanted catheter as required for other drugs in this class.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.celltherapeutics.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone in particular including, without limitation, the potential failure of pixantrone to prove safe and effective for treatment of relapsed aggressive NHL as determined by the FDA, the possibility that the New Drug Application submission will not be completed in the second quarter of 2009, that priority review will not be granted by the FDA and that a decision by the FDA is not rendered in late 2009, the company's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkins Lymphoma
2. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
3. Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkins Lymphoma Trial
4. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
5. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
6. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
7. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
8. Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
9. Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
10. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Mass. , Aug. 29, 2014  A ... prospective, multinational study on stent removability and preliminary ... has been published in the August issue of ... multinational study 1 is being conducted in ... of fully covered self-expanding metal stents (FCSEMS) after ...
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "China Orthopedic Instrument Industry Report, 2014-2017" report ... aging population and rising proportion of reimbursement for medical ... effectively released, with its scale presenting a CAGR of ... products are three product segments of orthopedic instruments in ...
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "Research and Development Trend Forecast of Pharmaceutical Equipment ... Research and Development Trend Forecast of ... 2014-2018 mainly analyzes China,s pharmaceutical ... supply & demand, competition landscape, and business performance of ...
Breaking Medicine Technology:Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4China Orthopedic Instrument Industry Report, 2014-2017 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2
... BETHLEHEM, Pa., June 22, 2011 In a ... of diazepam (NRL-1) achieved positive clinical results in ... was designed and manufactured at Particle Sciences.  In ... pharmacokinetic profile comparable to that reported in the ...
... The National Association of Public Hospitals and Health ... community for employees at its member hospitals, becoming one of ... Within3 online collaborative community. For the first time, NAPH ... local issues in an online forum, enabling continuous feedback and ...
Cached Medicine Technology:Particle Sciences Develops Proprietary Nasal Delivery Formulation Used in Neurelis' Recently Announced Successful Phase I Pharmacokinetic Study of NRL-01 (intranasal diazepam) 2National Association of Public Hospitals and Health Systems to Galvanize Member Relationships on Within3 2National Association of Public Hospitals and Health Systems to Galvanize Member Relationships on Within3 3
(Date:8/30/2014)... The therapeutic benefit of revascularisation in coronary artery ... revascularisation guidelines presented at ESC Congress by joint ... the European Society of Cardiology (ESC) and Professor ... Cardio-Thoracic Surgery (EACTS). The joint guidelines are published ... (1), on the ESC Website (2), in EuroIntervention ...
(Date:8/29/2014)... August 29, 2014 The Enchant Him review ... new program actually is a system that promises to teach ... was created by Carrie Engel, who actually is a popular ... users will get the best advices out there, Carrie worked ... , This new program is a simple to use ...
(Date:8/29/2014)... (PRWEB) August 30, 2014 Cancer ... loved ones and caretakers. Author Eddie M. Leung knows the ... cholangiocarcinoma or bile duct cancer, a very rare and ... That Changed My Life” (published by Xlibris), he shares a ... importantly, he imparts a survivor’s testimony that this disease can ...
(Date:8/29/2014)... The Fibroids Miracle review indicates that this is a new ... and powerful results. It actually claims to be able to ... 12 hours. The method promises to lead to a permanent ... on a 3 step method that has never been revealed ... was in fact created by someone who had an important ...
(Date:8/29/2014)... According to the latest review published by DailyGossip.org, ... quickly, safely and naturally. The new method promises great efficiency ... too. , Daily Gossip writes in its Flat Belly ... patients how to eliminate the extra pounds, it will also ... comes to body modeling. , The method reveals some ...
Breaking Medicine News(10 mins):Health News:ESC/EACTS revascularization guidelines stress benefit of revascularization in stable CAD 2Health News:ESC/EACTS revascularization guidelines stress benefit of revascularization in stable CAD 3Health News:Enchant Him Review Reveals Unique Relationship Tips for Women 2Health News:Eddie M. Leung Shares His Testimony As a Survivor of Cancer 2Health News:Eddie M. Leung Shares His Testimony As a Survivor of Cancer 3Health News:Fibroids Miracle Review Exposes Amanda Leto’s 3-Step Holistic System 2Health News:Flat Belly Forever Review Exposes the Way to Eliminate Body Fat Easily 2
... According to a research it was found that radiotherapy given ... against breast cancer//. The researchers from UK and US said ... the recurrence of cancer when compared to the conventional regime ... of the 10-year trial which was funded by the Cancer ...
... with stimulant medications rather than nonstimulant medications or ... such as mixed amphetamine salts (MAS) and methylphenidates ... medications such as modafinil. ,This conclusion is ... representing the past 25 years of research involving ...
... mobilisation against the disease in the last five years, frustrating ... UN says in advance of a review conference. ,A ... are scheduled to meet Wednesday-Friday at UN headquarters to assess ... General Assembly to try to reverse the epidemic by 2010. ...
... of genetically caused diseases from type 1 diabetes to alopecia, ... system, autoimmune disease can be understood//. ,By age ... infection of the skin and/or mucous membrane and adrenal gland ... in the Aire gene) and nearly about 16 autoimmune diseases ...
... were suffered, was caused by distinctly personal habits and ... do but to suffer in silence. Others like constipation, ... limiting some of their day-to-day activities. ,Researches ... modification instead of taking variety of drugs. ...
... statistics regarding the use of tobacco amongst teenagers, which has ... tobacco and its products. , ,These figures were made ... World No Tobacco Day; on May 31st. This years theme ... or disguise,'' conveying cigarette smoking in any form is extremely ...
Cached Medicine News:Health News:Stimulant Medications More Effective In Treating ADHD Than Nonstimulants 2Health News:Global War Against AIDS May Fail Target, Warns UN 2Health News:Autoimmune Diseases – Newer Preventive Measure 2Health News:Autoimmune Diseases – Newer Preventive Measure 3Health News:Silence Puts Comfort For Digestive Syndrome 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: